Newsletter Tool

To view this email as a web page, click here

Today's Rundown

AstraZeneca's having second thoughts about its COVID vaccine business as FDA filing drags on
Sanofi culls early infectious disease, blood disorder asset as it ramps up phase 3 for also-ran COVID vax
Emergent wins FDA all-clear to restart J&J COVID-19 vaccine production in Baltimore
CHS not worried about latest wave of COVID-19 impacting elective care
Thermo Fisher-bound PPD sees major sales jump for the first half, putting COVID chaos in the rearview mirror
Geisinger: Targeted messaging encouraged more employees to register for COVID-19 vaccination
Merck's HPV vaccine Gardasil rebounds from pandemic hit thanks to improved manufacturing capacity
COVID-19 tracker: Lilly's antibody given FDA all clear without remdesivir; Biden pushes states, cities to offer $100 for vaccinations

Featured Story

AstraZeneca's having second thoughts about its COVID vaccine business as FDA filing drags on

By Angus Liu

AstraZeneca’s COVID-19 vaccine has faced controversies ranging from clinical data clarity to harmful side effects. Now, as the shot takes even longer to reach the U.S., the drugmaker is having second thoughts about the business.

Sanofi culls early infectious disease, blood disorder asset as it ramps up phase 3 for also-ran COVID vax

By Ben Adams

Sanofi has made a small trim to its pipeline today, though its near-term R&D focus remains on the 35,000-strong COVID vaccine test it started last quarter.

Emergent wins FDA all-clear to restart J&J COVID-19 vaccine production in Baltimore

By Fraiser Kansteiner

Emergent won the FDA’s blessing to restart production of Johnson & Johnson’s COVID-19 vaccine at its Baltimore, Maryland, plant, the company said Thursday. The move follows “extensive” FDA reviews, plus “close coordination” with the agency and J&J on the quality enhancement plan Emergent debuted in May.

CHS not worried about latest wave of COVID-19 impacting elective care

By Robert King

Community Health Systems doesn't expect new surges of COVID-19 to cause a drop in elective care as the system's volumes start to rebound.

Thermo Fisher-bound PPD sees major sales jump for the first half, putting COVID chaos in the rearview mirror

By Ben Adams

PPD saw revenue jump just shy of 42% in the first half of the year as it continues its rebound from the dark days of 2020.

Geisinger: Targeted messaging encouraged more employees to register for COVID-19 vaccination

By Dave Muoio

The Pennsylvania health system saw vaccination registrations double shortly after sending individualized messages with behavioral science-informed content to nearly 10,000 healthcare workers who were unpersuaded by a prior mass email campaign.

Merck's HPV vaccine Gardasil rebounds from pandemic hit thanks to improved manufacturing capacity

By Kevin Dunleavy

With an increased supply capacity fueling a sales surge in China, Merck's HPV vaccine Gardasil is back on its pre-pandemic trajectory. Overall, the company reported a 22% increase in second-quarter revenues.

COVID-19 tracker: Lilly's antibody given FDA all clear without remdesivir; Biden pushes states, cities to offer $100 for vaccinations

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Eli Lilly's antibody baricitinib no longer needs to be administered alongside Gilead Science's remdesivir, the FDA said. President Joe Biden is pushing state and local governments to hand out $100 to those who get vaccinated against COVID-19. And more headlines.

COVID-19 Tracker